索拉非尼配合辨证中药汤剂治疗晚期原发性肝癌分析

Analysis on the Treatment of Advanced Primary Liver Cancer With Sola Fini and Chinese Herbal Decoction

目的探究晚期原发性肝癌患者接受索拉非尼与辨证中药汤剂联合治疗的价值。方法选取晚期原发性肝癌患者86例为本研究对象,时间为2015年3月—2018年1月,按照其治疗方案的差异分组,其中实验组实施索拉非尼与辨证中药汤剂联合治疗,对照组则实施索拉非尼治疗,对比2组晚期原发性肝癌患者治疗结果的差异性。结果实验组临床治疗获益率(76.74%)明显高于对照组的临床获益率(55.81%)(P<0.05);2组生存质量变化情况相比,之间差异无统计学意义(P>0.05)。结论晚期原发性肝癌患者接受索拉非尼与辨证中药汤剂联合治疗,对改善其预后意义重大。

Objective To explore the value of combination of Sola Fini and TCM Decoction in the treatment of advanced primary liver cancer.Methods The patients with advanced primary liver cancer in 86 cases as the research object,the time from March 2015 to January 2018,they were grouped according to their different treatment,the experimental group was treated with Sola Fini and herbal medicine,the control group was given the Sola Fini treatment,2 groups of advanced primary hepatocellular carcinoma patients with treatment outcome were compared.Results The clinical treatment benefit rate(76.74%)in the experimental group was significantly higher than that in the control group(55.81%)(P<0.05),and there was no significant difference in the quality of life between two groups(P>0.05).Conclusion The combination of Sola Fini and TCM Decoction in advanced primary liver cancer is of great significance in improving the prognosis of the patients with advanced primary liver cancer.